Voyager Therapeutics Price to Book Ratio 2014-2022 | VYGR

Historical price to book ratio values for Voyager Therapeutics (VYGR) over the last 10 years. The current price to book ratio for Voyager Therapeutics as of July 01, 2022 is 3.08.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Voyager Therapeutics Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2022-07-01 6.08 3.06
2022-03-31 7.62 $1.99 3.84
2021-12-31 2.71 $2.51 1.08
2021-09-30 2.63 $2.31 1.14
2021-06-30 4.13 $2.93 1.41
2021-03-31 4.71 $3.63 1.30
2020-12-31 7.15 $4.13 1.73
2020-09-30 10.67 $4.46 2.39
2020-06-30 12.62 $2.07 6.11
2020-03-31 9.15 $2.16 4.24
2019-12-31 13.95 $2.70 5.17
2019-09-30 17.21 $2.94 5.86
2019-06-30 27.22 $3.23 8.43
2019-03-31 19.14 $2.75 6.95
2018-12-31 9.40 $1.44 6.55
2018-09-30 18.92 $2.03 9.32
2018-06-30 19.54 $2.56 7.64
2018-03-31 18.79 $3.08 6.10
2017-12-31 16.60 $4.25 3.91
2017-09-30 20.59 $3.25 6.34
2017-06-30 8.96 $4.05 2.21
2017-03-31 13.24 $4.75 2.79
2016-12-31 12.74 $5.31 2.40
2016-09-30 12.01 $5.87 2.05
2016-06-30 10.99 $6.16 1.78
2016-03-31 8.73 $6.51 1.34
2015-12-31 21.90 $6.78 3.23
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.234B $0.037B
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00